How to buy Insmed Incorporated stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Insmed Incorporated stock

Own Insmed Incorporated stock in just a few minutes.

Insmed Incorporated is a biotechnology business based in the US. Insmed Incorporated shares (INSM) are listed on the NASDAQ and all prices are listed in US Dollars. Insmed Incorporated employs 521 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Insmed Incorporated

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INSM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Insmed Incorporated share price

Use our graph to track the performance of INSM stocks over time.

Insmed Incorporated shares at a glance

Information last updated 2021-04-15.
52-week range$18.58 - $45.44
50-day moving average $35.87
200-day moving average $36.97
Wall St. target price$53.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.09

Buy Insmed Incorporated shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Insmed Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Insmed Incorporated financials

Revenue TTM $164.4 million
Gross profit TTM $124.5 million
Return on assets TTM -21.55%
Return on equity TTM -109.42%
Profit margin -178.87%
Book value $2.69
Market capitalisation $3.5 billion

TTM: trailing 12 months

Shorting Insmed Incorporated shares

There are currently 8.8 million Insmed Incorporated shares held short by investors – that's known as Insmed Incorporated's "short interest". This figure is 2.5% up from 8.6 million last month.

There are a few different ways that this level of interest in shorting Insmed Incorporated shares can be evaluated.

Insmed Incorporated's "short interest ratio" (SIR)

Insmed Incorporated's "short interest ratio" (SIR) is the quantity of Insmed Incorporated shares currently shorted divided by the average quantity of Insmed Incorporated shares traded daily (recently around 1.2 million). Insmed Incorporated's SIR currently stands at 7.21. In other words for every 100,000 Insmed Incorporated shares traded daily on the market, roughly 7210 shares are currently held short.

However Insmed Incorporated's short interest can also be evaluated against the total number of Insmed Incorporated shares, or, against the total number of tradable Insmed Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Insmed Incorporated's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Insmed Incorporated shares in existence, roughly 90 shares are currently held short) or 0.1104% of the tradable shares (for every 100,000 tradable Insmed Incorporated shares, roughly 110 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Insmed Incorporated.

Find out more about how you can short Insmed Incorporated stock.

Insmed Incorporated share dividends

We're not expecting Insmed Incorporated to pay a dividend over the next 12 months.

Have Insmed Incorporated's shares ever split?

Insmed Incorporated's shares were split on a 1:10 basis on 2 March 2011. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Insmed Incorporated shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Insmed Incorporated shares which in turn could have impacted Insmed Incorporated's share price.

Insmed Incorporated share price volatility

Over the last 12 months, Insmed Incorporated's shares have ranged in value from as little as $18.58 up to $45.44. A popular way to gauge a stock's volatility is its "beta".

INSM.US volatility(beta: 2.31)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Insmed Incorporated's is 2.3094. This would suggest that Insmed Incorporated's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Insmed Incorporated overview

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site